ifosfamide has been researched along with Sepsis in 11 studies
Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
| Excerpt | Relevance | Reference |
|---|---|---|
| " ifosfamide (5 g/m(2)), carboplatin (300 mg/m(2)) and etoposide (150 mg/m(2) on days 2 and 3), administered every 4 weeks, for patients with malignant pleural mesothelioma." | 9.10 | Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma. ( Bakhshandeh, A; Bruns, I; Dalhoff, K; Demedts, A; Eberhardt, K; Ehlers, EM; Gatzemeier, U; Gruber, Y; Hegewisch-Becker, S; Kaukel, E; Kohlmann, T; Koschel, G; Peters, SO; Robins, HI; Traynor, A; Wiedemann, GJ; Zumschlinge, R, 2003) |
| " ifosfamide and etoposide) and to improve overall survival of previously untreated patients with metastatic rhabdomyosarcoma." | 9.09 | Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. ( Breitfeld, PP; Crist, WM; Donaldson, SS; Lobe, T; Lyden, E; Maurer, HM; Raney, RB; Ruymann, FB; Teot, LA; Wharam, M, 2001) |
| "Three patients with stage 4 neuroblastoma were treated with a schedule comprising alternating modules of myelosuppressive (ifosfamide, etoposide, doxorubicin) and less myelosuppressive (vincristine, cisplatin) drugs given every 10 days regardless of the neutrophil count." | 9.07 | Prohibitive toxicity of a dose-intense regime for metastatic neuroblastoma containing ifosfamide, doxorubicin and cisplatin. ( Craft, AW; Lowis, SP; Pearson, AD; Reid, MM, 1993) |
| "Seven treatment-related deaths due to septicemia (three), cardiac arrhythmia (one), pneumonia (one), pneumonitis (one), and toxic epidermal necrolysis (one) were observed." | 6.73 | Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. ( Ebeling, P; Metz, K; Moritz, T; Müller, S; Nowrousian, MR; Passon, J; Schütt, P; Seeber, S; Welt, A, 2007) |
| " ifosfamide (5 g/m(2)), carboplatin (300 mg/m(2)) and etoposide (150 mg/m(2) on days 2 and 3), administered every 4 weeks, for patients with malignant pleural mesothelioma." | 5.10 | Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma. ( Bakhshandeh, A; Bruns, I; Dalhoff, K; Demedts, A; Eberhardt, K; Ehlers, EM; Gatzemeier, U; Gruber, Y; Hegewisch-Becker, S; Kaukel, E; Kohlmann, T; Koschel, G; Peters, SO; Robins, HI; Traynor, A; Wiedemann, GJ; Zumschlinge, R, 2003) |
| " ifosfamide and etoposide) and to improve overall survival of previously untreated patients with metastatic rhabdomyosarcoma." | 5.09 | Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. ( Breitfeld, PP; Crist, WM; Donaldson, SS; Lobe, T; Lyden, E; Maurer, HM; Raney, RB; Ruymann, FB; Teot, LA; Wharam, M, 2001) |
| "Three patients with stage 4 neuroblastoma were treated with a schedule comprising alternating modules of myelosuppressive (ifosfamide, etoposide, doxorubicin) and less myelosuppressive (vincristine, cisplatin) drugs given every 10 days regardless of the neutrophil count." | 5.07 | Prohibitive toxicity of a dose-intense regime for metastatic neuroblastoma containing ifosfamide, doxorubicin and cisplatin. ( Craft, AW; Lowis, SP; Pearson, AD; Reid, MM, 1993) |
| "Seven treatment-related deaths due to septicemia (three), cardiac arrhythmia (one), pneumonia (one), pneumonitis (one), and toxic epidermal necrolysis (one) were observed." | 2.73 | Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. ( Ebeling, P; Metz, K; Moritz, T; Müller, S; Nowrousian, MR; Passon, J; Schütt, P; Seeber, S; Welt, A, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Totadri, S | 1 |
| Bansal, D | 1 |
| Rao, KLN | 1 |
| Jain, R | 1 |
| Saxena, AK | 1 |
| Kapoor, R | 1 |
| Samujh, R | 1 |
| Trehan, A | 1 |
| Bakhshandeh, A | 1 |
| Bruns, I | 1 |
| Traynor, A | 1 |
| Robins, HI | 1 |
| Eberhardt, K | 1 |
| Demedts, A | 1 |
| Kaukel, E | 1 |
| Koschel, G | 1 |
| Gatzemeier, U | 1 |
| Kohlmann, T | 1 |
| Dalhoff, K | 1 |
| Ehlers, EM | 1 |
| Gruber, Y | 1 |
| Zumschlinge, R | 1 |
| Hegewisch-Becker, S | 1 |
| Peters, SO | 1 |
| Wiedemann, GJ | 1 |
| Davidson, KL | 1 |
| Devaney, MB | 1 |
| Tighe, JE | 1 |
| Rogers, SY | 1 |
| Dunlop, DJ | 1 |
| Mackie, MJ | 1 |
| Thomas, RV | 1 |
| Johnson, PR | 1 |
| Schütt, P | 1 |
| Passon, J | 1 |
| Ebeling, P | 1 |
| Welt, A | 1 |
| Müller, S | 1 |
| Metz, K | 1 |
| Moritz, T | 1 |
| Seeber, S | 1 |
| Nowrousian, MR | 1 |
| Lowis, SP | 1 |
| Pearson, AD | 1 |
| Reid, MM | 1 |
| Craft, AW | 1 |
| Chen, YM | 1 |
| Wu, MF | 1 |
| Perng, RP | 1 |
| Chou, CM | 1 |
| Yang, KY | 1 |
| Lin, WC | 1 |
| Tsai, CM | 1 |
| Liu, JM | 1 |
| Whang-Peng, J | 1 |
| Theis, JG | 2 |
| Chan, HS | 2 |
| Greenberg, ML | 2 |
| Malkin, D | 2 |
| Karaskov, V | 2 |
| Moncica, I | 2 |
| Koren, G | 2 |
| Doyle, J | 2 |
| Krämer, A | 1 |
| Andrassy, K | 1 |
| Ho, AD | 1 |
| Breitfeld, PP | 1 |
| Lyden, E | 1 |
| Raney, RB | 1 |
| Teot, LA | 1 |
| Wharam, M | 1 |
| Lobe, T | 1 |
| Crist, WM | 1 |
| Maurer, HM | 1 |
| Donaldson, SS | 1 |
| Ruymann, FB | 1 |
| Ghosn, M | 1 |
| Droz, JP | 1 |
| Theodore, C | 1 |
| Pico, JL | 1 |
| Baume, D | 1 |
| Spielmann, M | 1 |
| Ostronoff, M | 1 |
| Moran, A | 1 |
| Salloum, E | 1 |
| Kramar, A | 1 |
7 trials available for ifosfamide and Sepsis
| Article | Year |
|---|---|
Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Dexame | 2003 |
A pilot study of CODOX-M/IVAC in primary refractory or relapsed high-grade non-Hodgkin's lymphoma. A Scotland and Newcastle Lymphoma Group Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 2003 |
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Thera | 2007 |
Prohibitive toxicity of a dose-intense regime for metastatic neuroblastoma containing ifosfamide, doxorubicin and cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Child, Preschool; C | 1993 |
Phase II study of ifosfamide and etoposide chemotherapy for extensive-disease small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Small Cell; Drug Admin | 1997 |
Increased systemic toxicity of sarcoma chemotherapy due to combination with the P-glycoprotein inhibitor cyclosporin.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe | 1998 |
Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bronchiolit | 2001 |
4 other studies available for ifosfamide and Sepsis
| Article | Year |
|---|---|
Challenges in the management of localized Ewing sarcoma in a developing country.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 2020 |
Assessment of systemic toxicity in children receiving chemotherapy with cyclosporine for sarcoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplasti | 2000 |
Renal failure after bone marrow transplantation.
Topics: Acute Kidney Injury; Bone Marrow Transplantation; Humans; Ifosfamide; Immunosuppressive Agents; Kidn | 2001 |
Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhP regimen.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cisplatin; Etopo | 1988 |